Back to Authors

Aghevli, Ariana

Mayo Clinic

Mayo Clinic

Citations 2

CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease
Cao, Yingshu , Sun, Xiaobo , Huang, Yan , Ji, Biyun , Chen, Renee , Li, Yuan , Liang, Yan , Aghevli, Ariana, Patel, Vishal , Harris, Peter C. , Ling, Kun , Hu, Jinghua , Chen, Chuan , Ji, Biyun , Chen, Renee , Liang, Yan , Yang, Nicole, Patel, Vishal , Harris, Peter C , Ling, Kun , He, Kai , Chen, Chuan , Yang, Nicole, He, Kai

Journal of the American Society of Nephrology | September 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1681/asn.0000001269 Get It

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disorder leading to kidney failure. Tolvaptan, the only FDA-approved therapy, modestly slows disease progression but is limited by significant adverse effects, highlighting the need for more effective and better-tolerated treatments. Ciliary polycystins are central to ADPKD pathogenesis. We previously demonstrated that a cilia base-localized pool of CDK6 restricts ciliary polycystin abundance by suppressing axonemal polyglutamylation. However, whether CDK6 inhibition can restore polycystin function and suppress ADPKD progression in vivo remains unknown. Methods: Abemaciclib was tested in in vitro 3D cyst assays and ex vivo metanephric organ cultures. In vivo efficacy of early- and late-stage intervention were assessed in F1(129/B6) Pkd1 R3277C/R3277C mice receiving daily abemaciclib. Tolvaptan served as a therapeutic control. Cyst burden, fibrosis in the kidneys, kidney function, and primary cilia of renal epithelial cells were analyzed at study endpoints. Results: CDK6 was prominently upregulated in cyst-lining cells in human and murine PKD kidneys. At doses substantially lower than those used in oncology, abemaciclib robustly suppressed cyst growth in vitro and ex vivo . In vivo , long-term early treatment arrested cyst progression more effectively than tolvaptan without detectable toxicity. Late intervention largely halted cyst growth in females and reversed cyst progression in males. Mechanistically, abemaciclib restored axonemal polyglutamylation and increased ciliary polycystin levels. Conclusions: Abemaciclib has greater therapeutic efficacy and tolerability than tolvaptan in this preclinical model, largely driven by CDK6 inhibition–mediated restoration of axonemal polyglutamylation and increased ciliary polycystin abundance.
A Ciliary Phosphoinositide Pathway Regulates the Dosage of Polycystins in Primary Cilia
Wang, Zhifei , Ellis, Madilyn R. , Ji, Biyun , Sieben, Cynthia J. , Haycraft, Courtney J. , Croyle, Mandy J. , Aghevli, Ariana, Xu, Qingwen , Robichaud, Jielu Hao, Huang, Yan , Yoder, Bradley K. , Hu, Jinghua , Yu, Yong , Ling, Kun , Chen, Chuan , Wang, Zhifei , Gao, Yue, Ellis, Madilyn R , Ji, Biyun , Sieben, Cynthia J , Croyle, Mandy , Xu, Qingwen , Robichaud, Jielu H, He, Kai , Huang, Yan , Yoder, Bradley K , Harris, Peter C , Yu, Yong , Ling, Kun , Chen, Chuan , Gao, Yue , Hao, Jielu , He, Kai , Chen, Chunhua , Harris, Peter C.

Journal of the American Society of Nephrology | November 25, 2025 | Volume: 37 | Issue: 5 | Pages: 944-958

10.1681/asn.0000000942 Get It

Key Points Inositol polyphosphate-5-phosphatase E (INPP5E) and type Ig phosphatidylinositol-4-phosphate 5-kinase (PIPKIγ) coordinated the homeostasis of phosphatidylinositol-4-phosphate and phosphatidylinositol-4,5-bisphosphate in primary cilia. Modulating INPP5E or PIPKIγ activity changed the level of polycystin-1 and polycystin-2 in primary cilia. INPP5E inhibition increased the hypomorphic PKD1 variants (PC1-R3277C) in cilia and reduced cystogenesis in the kidney in vitro . Background Autosomal dominant polycystic kidney disease is mainly caused by mutations in PKD1 and PKD2 , which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC1 and PC2 assemble a cation channel complex enriched in primary cilium, a sensory organelle associated with various developmental diseases, including polycystic kidney disease (PKD). Accumulating evidence supports the necessity of functional polycystin (PC) complex in cilia to prevent cystogenesis in the kidney, indicating that improving their ciliary levels may ameliorate defects underlying PKD pathogenesis. Yet, molecular mechanisms underlying the ciliary targeting and homeostasis of the PC complex are not fully understood. Methods Indirect immunofluorescence microscopy was used to monitor ciliary levels of PC1 and PC2 in renal epithelial cells. Electrophysiology analysis in oocytes was used to determine the channel activity of the PC complex. Cystogenesis in the kidney was measured using in vitro 3D-Matrigel cell models and ex vivo mouse embryonic kidney models. Results Suppressing inositol polyphosphate-5-phosphatase E (INPP5E) or activating type Ig phosphatidylinositol-4-phosphate 5-kinase raised ciliary levels of the PC complex in both normal renal epithelial cells and cells carrying autosomal dominant polycystic kidney disease mutations that interrupt the trafficking of PCs into cilia, including GANAB inactivation and the trafficking PKD1 mutation p.Arg3277Cys (RC). PC1 RC formed a complex with PC2 and exhibited normal channel activity in vitro . An INPP5E that increases PC1 and PC2 in cilia, suppressed in vitro forskolin-induced cystogenesis of inner medullary collecting duct epithelial cell line 3 cells in 3D Matrigel and ex vivo cyst formation in embryonic Pkd1 RC/RC mouse kidneys. Conclusions Our results demonstrated that increasing the ciliary level of PCs, by manipulating a ciliary phosphoinositide signaling axis, enhanced the functionality of PCs and suppressed cystogenesis of renal epithelial cells in vitro .